Maxcyte (MXCT) Net Margin (2020 - 2025)
Maxcyte (MXCT) has disclosed Net Margin for 6 consecutive years, with 269.74% as the latest value for Q3 2025.
- On a quarterly basis, Net Margin fell 6380.0% to 269.74% in Q3 2025 year-over-year; TTM through Sep 2025 was 238.29%, a 10432.0% decrease, with the full-year FY2024 number at 184.81%, up 970.0% from a year prior.
- Net Margin was 269.74% for Q3 2025 at Maxcyte, down from 145.26% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 26.44% in Q3 2021 to a low of 3580.07% in Q4 2024.
- A 5-year average of 321.41% and a median of 111.0% in 2023 define the central range for Net Margin.
- Peak YoY movement for Net Margin: skyrocketed 28371bps in 2023, then plummeted -346907bps in 2024.
- Maxcyte's Net Margin stood at 48.02% in 2021, then decreased by -29bps to 62.01% in 2022, then tumbled by -79bps to 111.0% in 2023, then crashed by -3125bps to 3580.07% in 2024, then surged by 92bps to 269.74% in 2025.
- Per Business Quant, the three most recent readings for MXCT's Net Margin are 269.74% (Q3 2025), 145.26% (Q2 2025), and 178.67% (Q1 2025).